Intra-Cellular Therapies Inc (ITCI)
70.35
-2.32
(-3.19%)
USD |
NASDAQ |
May 02, 16:00
70.35
0.00 (0.00%)
After-Hours: 17:37
Intra-Cellular Therapies Revenue (Quarterly): 131.51M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 131.51M |
| September 30, 2023 | 125.81M |
| June 30, 2023 | 110.13M |
| March 31, 2023 | 94.73M |
| December 31, 2022 | 87.43M |
| September 30, 2022 | 71.87M |
| June 30, 2022 | 55.07M |
| March 31, 2022 | 34.76M |
| December 31, 2021 | 25.52M |
| September 30, 2021 | 21.61M |
| June 30, 2021 | 19.01M |
| March 31, 2021 | 15.58M |
| December 31, 2020 | 12.40M |
| September 30, 2020 | 7.369M |
| June 30, 2020 | 1.876M |
| March 31, 2020 | 0.8825M |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 |
| Date | Value |
|---|---|
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 0.0051M |
| September 30, 2017 | 0.0308M |
| June 30, 2017 | 0.1147M |
| March 31, 2017 | 0.0953M |
| December 31, 2016 | 0.0979M |
| September 30, 2016 | 0.0044M |
| June 30, 2016 | 0.2284M |
| March 31, 2016 | |
| December 31, 2015 | -0.03M |
| September 30, 2015 | |
| June 30, 2015 | 0.0574M |
| March 31, 2015 | 0.0033M |
| December 31, 2014 | 0.0361M |
| September 30, 2014 | 0.1244M |
| June 30, 2014 | 0.2192M |
| March 31, 2014 | 0.1678M |
| December 31, 2013 | 0.8275M |
| September 30, 2013 | 0.668M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.8825M
Minimum
Mar 2020
131.51M
Maximum
Dec 2023
50.97M
Average
30.14M
Median
Revenue (Quarterly) Benchmarks
| Johnson & Johnson | 21.38B |
| Insmed Inc | 83.69M |
| Vertex Pharmaceuticals Inc | 2.518B |
| Fate Therapeutics Inc | 1.676M |
| ADMA Biologics Inc | 73.90M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -28.58M |
| Total Expenses (Quarterly) | 165.60M |
| EPS Diluted (Quarterly) | -0.30 |
| Enterprise Value | 6.537B |
| Gross Profit Margin (Quarterly) | 91.86% |
| Profit Margin (Quarterly) | -21.73% |
| Earnings Yield | -2.08% |
| Normalized Earnings Yield | -2.075 |